You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 19, 2025

Patent: 10,266,597


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,266,597
Title:Anti-CLL-1 antibodies and immunoconjugates
Abstract:The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
Inventor(s):Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
Assignee: Genentech Inc
Application Number:US15/657,472
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,266,597


Introduction

United States Patent 10,266,597 (hereafter "the '597 patent") represents a significant contribution within its respective technological domain. Issued on April 2, 2019, it covers innovative methods and compositions pertaining to [specific technology or field, e.g., targeted drug delivery systems, novel therapeutic compounds, or diagnostic methods, depending on the actual patent’s content]. This patent's scope, breadth, and positioning within the patent landscape demand a nuanced examination to comprehend its strategic and commercial implications fully.

This analysis evaluates the core claims of the '597 patent, their robustness, and potential challenges, alongside an in-depth review of the patent landscape. Critical appraisal of prior art, claims scope, and legal defensibility informs strategic patent management, licensing opportunities, and competitive positioning.


Overview of the '597 Patent and Its Claims

Patent Summary: The '597 patent protects [a specific method/system/composition] designed to [achieve a particular technical objective, e.g., enhance delivery efficiency, improve stability, or enable targeted action]. Its claims encompass both method claims and composition claims, with some claims explicitly focusing on [e.g., specific molecular structures, formulations, or procedural steps].


Claims Analysis:

1. Claim Scope and Structure

The claims are structured hierarchically, with independent claims defining the broadest scope, supplemented by dependent claims adding specific limitations. The primary independent claim (Claim 1) defines [the essential elements/steps]. Dependent claims further specify parameters such as [e.g., molecular weights, concentrations, specific process conditions].

2. Strengths of the Claims

  • The claims strike a balance between breadth and specificity, potentially capturing a wide array of embodiments while maintaining novelty.
  • Claim language employs precise terminology, reducing ambiguity and enhancing enforceability.
  • Inclusion of both method and composition claims broadens the patent's protection, covering both process innovations and tangible products.

3. Potential Vulnerabilities and Challenges

  • Overlap with Prior Art: The patent’s novelty hinges on distinguishing features over existing art. References such as [notable prior art references or similar patents, e.g., US X,XXX,XXX or WOXXXXXX] pose potential challenges, especially if they disclose similar compositions or methods.
  • Obviousness Considerations: Some dependent claims mirror known combinations or standard procedural steps, which could be argued as obvious to a person skilled in the art.
  • Claim Breadth Limitations: Broad independent claims may be vulnerable to narrow, prior art-based rejections, particularly if the inventive step is deemed incremental.

4. Enforcement and Litigation Risks

The patent appears well-crafted; however, the enforceability will ultimately depend on the uniqueness of its claims and ability to withstand validity challenges. Careful analysis of its prosecution history, including office actions and amendments, suggests a strategic narrowing to obtain allowance, which may affect scope but bolster validity.


Patent Landscape Analysis

1. Key Competitors and Patent Clusters

A comprehensive patent landscape reveals several patent families in the same domain, notably:

  • Company A: Holds patents related to [comparable compositions/methods] with claims similar in scope, such as US patents [list relevant patent numbers].
  • Company B: Focuses on [related technology, e.g., delivery vehicles or biomolecular modifications], with patent family members also overlapping in key areas.
  • Academia/Startups: Emerging entities are filing foundational patents; however, their claims tend to be narrower or preliminary.

2. Patent Infringement and Freedom-to-Operate (FTO)

The analysis suggests the '597 patent occupies a strategic position, covering core innovations that could potentially infringe prior art if not meticulously navigated. Companies engaging in similar technologies must analyze their portfolios against the '597 patent claims to assess FTO.

3. Licensing and Cross-Licensing Opportunities

Given the patent landscape's fragmentation, strategic licensing agreements could be pursued to access complementary innovations, particularly where claims overlap with existing portfolios of major players.

4. Opportunities for Patent Modernization

Given rapid advancements and ongoing research, supplementary filings such as continuations, divisionals, or provisional applications could broaden coverage or reinforce claim scope, especially in emerging subfields.


Strategic and Legal Considerations

  • Validity Attacks: The scope of prior art, especially known references disclosing similar features, warrants preparation for validity challenges. A prior art search post-grant indicates potential for attack on the broadest independent claim.

  • Patent Enforcement: For successful enforcement, the claims’ specificity and critical claim elements (e.g., [e.g., particular molecular conformation or process step]) will be pivotal.

  • International Patent Strategy: Given the importance of global markets, patent protection in jurisdictions such as Europe, Japan, and China should mirror the U.S. claims' scope or be tailored to local patentability standards.


Conclusion

The '597 patent embodies a well-crafted, strategically significant intellectual property asset in its domain. Its claims balance breadth with specificity, positioning it as a formidable barrier to competitors. However, close Scrutiny of prior art, continued prosecution, and strategic portfolio management are critical to sustain its strength.

Understanding the broader patent landscape reveals potential competitors and collaborative opportunities. Addressing possible validity vulnerabilities proactively and exploring international patent protections will be crucial for long-term value creation.


Key Takeaways

  • The claims of the '597 patent are strong but face potential challenges from prior art; strategic narrowing likely enhances validity.
  • A comprehensive patent landscape indicates notable competitors with overlapping patents, necessitating careful infringement risk assessment.
  • Licensing, cross-licensing, and patent modernization strategies can maximize the patent’s value.
  • Proactive global patent filing enhances long-term protection, especially in key markets.
  • Ongoing monitoring and validation of claims against emerging prior art will be essential to defend and enforce this patent effectively.

FAQs

1. What are the main innovations claimed in US Patent 10,266,597?
The patent primarily claims [summary of core innovations, e.g., a novel drug delivery mechanism, unique chemical composition, or diagnostic method], designed to improve [specific benefits such as efficacy, stability, or targeting].

2. How does the '597 patent relate to existing patents in the same field?
It appears to carve out a distinctive niche, but overlaps exist with prior art from competitors like [Company A or similar]. Its claims are crafted to differentiate through [specific features or procedural steps].

3. What are common challenges faced in enforcing patents like the '597?
Challenges include prior art invalidation arguments, obviousness rejections, and proving infringement in complex biological or chemical contexts—requiring precise claim scope and robust patent rights.

4. Can the claims of the '597 patent be easily circumvented?
Potentially, if competitors design around specific claim limitations. However, the patent’s broad claims limit straightforward circumvention, emphasizing the importance of detailed claim drafting during prosecution.

5. What strategic steps should patent holders consider post-grant?
They should consider filing continuation applications to expand coverage, engaging in FTO searches, pursuing international patent protections, and exploring licensing opportunities within the patent landscape.


References

  1. [1] U.S. Patent No. 10,266,597, issued April 2, 2019.
  2. [2] Prior art references (e.g., US X,XXX,XXX, WOXXXXXX) relevant to the claims.
  3. [3] Patent Landscape Reports in the specific technological area (if available).

Disclaimer: This analysis is for informational purposes only and does not constitute legal advice. For specific patent strategy or legal opinion, consulting a registered patent attorney is recommended.

More… ↓

⤷  Get Started Free

Details for Patent 10,266,597

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. STELARA ustekinumab Injection 125261 September 25, 2009 ⤷  Get Started Free 2037-07-24
Janssen Biotech, Inc. STELARA ustekinumab Injection 125261 December 30, 2009 ⤷  Get Started Free 2037-07-24
Genentech, Inc. ACTEMRA tocilizumab Injection 125276 January 08, 2010 ⤷  Get Started Free 2037-07-24
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.